Best products for acne & breakouts

Systematic review of keratolytics and emollients in psoriasis therapy: salicylic acid is a key keratolytic that removes psoriatic scale and improves penetration of co-applied topical agents; supports salicylic acid as an evidence-based adjunctive (descaling) treatment rather than a standalone therapy.

Comprehensive review: salicylic acid (2%) is the only lipophilic BHA, enabling comedolytic and anti-inflammatory activity within the pilosebaceous unit; effective for acne vulgaris, melasma, photodamage, and keratosis pilaris; 20-30% SA peels show efficacy comparable to glycolic acid peels with lower erythema risk in Fitzpatrick IV-VI

Single-blind RCT (n=46, 12 weeks) in mild-to-moderate acne comparing salicylic acid 3% plus clindamycin with tretinoin 0.05% plus clindamycin: both significantly reduced inflammatory and non-inflammatory lesion counts; tretinoin acted faster (significant by week 2) but groups were comparable at 12 weeks, and both were well tolerated.

This review of four placebo-controlled clinical studies and a comedolytic assay found that 0.5% and 2% salicylic acid pads reduced the number and severity of acne lesions in mild-to-moderate acne vulgaris. Comparative data showed salicylic acid superior to benzoyl peroxide, with adverse effects limited to mild local irritation.

Randomized controlled trial (n=25): Pivotal skin of color salicylic peel evidence for acne PIH melasma oily skin.

Randomized controlled trial: Salicylic vs Jessner equivalent efficacy better tolerability for salicylic.

Randomized controlled trial: Comparable efficacy of salicylic to Jessner.

Clinical study: Salicylic peel for photoaging secondary indication.

Clinical study: Direct head to head AHA vs BHA for acne.

Clinical study: Definitive evidence that salicylic does NOT increase UV sensitivity unlike glycolic; key differentiator from AHA family.

Systematic review of keratolytics and emollients in psoriasis therapy: salicylic acid is a key keratolytic that removes psoriatic scale and improves penetration of co-applied topical agents; supports salicylic acid as an evidence-based adjunctive (descaling) treatment rather than a standalone therapy.

Comprehensive review: salicylic acid (2%) is the only lipophilic BHA, enabling comedolytic and anti-inflammatory activity within the pilosebaceous unit; effective for acne vulgaris, melasma, photodamage, and keratosis pilaris; 20-30% SA peels show efficacy comparable to glycolic acid peels with lower erythema risk in Fitzpatrick IV-VI

Single-blind RCT (n=46, 12 weeks) in mild-to-moderate acne comparing salicylic acid 3% plus clindamycin with tretinoin 0.05% plus clindamycin: both significantly reduced inflammatory and non-inflammatory lesion counts; tretinoin acted faster (significant by week 2) but groups were comparable at 12 weeks, and both were well tolerated.

This review of four placebo-controlled clinical studies and a comedolytic assay found that 0.5% and 2% salicylic acid pads reduced the number and severity of acne lesions in mild-to-moderate acne vulgaris. Comparative data showed salicylic acid superior to benzoyl peroxide, with adverse effects limited to mild local irritation.

Randomized controlled trial (n=25): Pivotal skin of color salicylic peel evidence for acne PIH melasma oily skin.

Randomized controlled trial: Salicylic vs Jessner equivalent efficacy better tolerability for salicylic.

Randomized controlled trial: Comparable efficacy of salicylic to Jessner.

Clinical study: Salicylic peel for photoaging secondary indication.

Clinical study: Direct head to head AHA vs BHA for acne.

Clinical study: Definitive evidence that salicylic does NOT increase UV sensitivity unlike glycolic; key differentiator from AHA family.

Meta-analysis: Meta analysis of five RCTs confirming adapalene class effect.

Randomized controlled trial (n=653, 12 weeks): Pivotal adapalene 0.3 vs 0.1 vs vehicle phase 3.

0.3% adapalene achieved superior reduction in inflammatory and non-inflammatory lesions vs 0.1%, with acceptable tolerability.

Comparable acne reduction to tretinoin with significantly less irritation, dryness, and erythema.

Clinical study (n=551, 52 weeks): Long term safety and efficacy 52 week.

Chemical/photostability testing: adapalene remained stable under visible light and UV irradiation (alone and combined with benzoyl peroxide), whereas tretinoin degraded substantially under the same conditions, supporting adapalene's superior photostability.

Randomized controlled trial (n=609, 12 weeks): Replicates Mills 1986 finding in Asian skin with larger n; 72.7% vs 75.0% vs 41.7% lesion reduction 2.5 vs 5 vs placebo.

Randomized controlled trial (n=153, 8 weeks): Efficacy equivalence across concentrations with tolerability advantage for 2.5%.

Systematic review: Current evidence synthesis confirming BPO efficacy for acne moderate certainty of evidence.

Randomized controlled trial: 2024 FDA approved triple combination product evidence; represents current state of art acne combination therapy.

Systematic review of keratolytics and emollients in psoriasis therapy: salicylic acid is a key keratolytic that removes psoriatic scale and improves penetration of co-applied topical agents; supports salicylic acid as an evidence-based adjunctive (descaling) treatment rather than a standalone therapy.

Comprehensive review: salicylic acid (2%) is the only lipophilic BHA, enabling comedolytic and anti-inflammatory activity within the pilosebaceous unit; effective for acne vulgaris, melasma, photodamage, and keratosis pilaris; 20-30% SA peels show efficacy comparable to glycolic acid peels with lower erythema risk in Fitzpatrick IV-VI

Single-blind RCT (n=46, 12 weeks) in mild-to-moderate acne comparing salicylic acid 3% plus clindamycin with tretinoin 0.05% plus clindamycin: both significantly reduced inflammatory and non-inflammatory lesion counts; tretinoin acted faster (significant by week 2) but groups were comparable at 12 weeks, and both were well tolerated.

This review of four placebo-controlled clinical studies and a comedolytic assay found that 0.5% and 2% salicylic acid pads reduced the number and severity of acne lesions in mild-to-moderate acne vulgaris. Comparative data showed salicylic acid superior to benzoyl peroxide, with adverse effects limited to mild local irritation.

Randomized controlled trial (n=25): Pivotal skin of color salicylic peel evidence for acne PIH melasma oily skin.

Randomized controlled trial: Salicylic vs Jessner equivalent efficacy better tolerability for salicylic.

Randomized controlled trial: Comparable efficacy of salicylic to Jessner.

Clinical study: Salicylic peel for photoaging secondary indication.

Clinical study: Direct head to head AHA vs BHA for acne.

Clinical study: Definitive evidence that salicylic does NOT increase UV sensitivity unlike glycolic; key differentiator from AHA family.

Systematic review of keratolytics and emollients in psoriasis therapy: salicylic acid is a key keratolytic that removes psoriatic scale and improves penetration of co-applied topical agents; supports salicylic acid as an evidence-based adjunctive (descaling) treatment rather than a standalone therapy.

Comprehensive review: salicylic acid (2%) is the only lipophilic BHA, enabling comedolytic and anti-inflammatory activity within the pilosebaceous unit; effective for acne vulgaris, melasma, photodamage, and keratosis pilaris; 20-30% SA peels show efficacy comparable to glycolic acid peels with lower erythema risk in Fitzpatrick IV-VI

Single-blind RCT (n=46, 12 weeks) in mild-to-moderate acne comparing salicylic acid 3% plus clindamycin with tretinoin 0.05% plus clindamycin: both significantly reduced inflammatory and non-inflammatory lesion counts; tretinoin acted faster (significant by week 2) but groups were comparable at 12 weeks, and both were well tolerated.

This review of four placebo-controlled clinical studies and a comedolytic assay found that 0.5% and 2% salicylic acid pads reduced the number and severity of acne lesions in mild-to-moderate acne vulgaris. Comparative data showed salicylic acid superior to benzoyl peroxide, with adverse effects limited to mild local irritation.

Randomized controlled trial (n=25): Pivotal skin of color salicylic peel evidence for acne PIH melasma oily skin.

Randomized controlled trial: Salicylic vs Jessner equivalent efficacy better tolerability for salicylic.

Randomized controlled trial: Comparable efficacy of salicylic to Jessner.

Clinical study: Salicylic peel for photoaging secondary indication.

Clinical study: Direct head to head AHA vs BHA for acne.

Clinical study: Definitive evidence that salicylic does NOT increase UV sensitivity unlike glycolic; key differentiator from AHA family.

Systematic review of keratolytics and emollients in psoriasis therapy: salicylic acid is a key keratolytic that removes psoriatic scale and improves penetration of co-applied topical agents; supports salicylic acid as an evidence-based adjunctive (descaling) treatment rather than a standalone therapy.

Comprehensive review: salicylic acid (2%) is the only lipophilic BHA, enabling comedolytic and anti-inflammatory activity within the pilosebaceous unit; effective for acne vulgaris, melasma, photodamage, and keratosis pilaris; 20-30% SA peels show efficacy comparable to glycolic acid peels with lower erythema risk in Fitzpatrick IV-VI

Single-blind RCT (n=46, 12 weeks) in mild-to-moderate acne comparing salicylic acid 3% plus clindamycin with tretinoin 0.05% plus clindamycin: both significantly reduced inflammatory and non-inflammatory lesion counts; tretinoin acted faster (significant by week 2) but groups were comparable at 12 weeks, and both were well tolerated.

This review of four placebo-controlled clinical studies and a comedolytic assay found that 0.5% and 2% salicylic acid pads reduced the number and severity of acne lesions in mild-to-moderate acne vulgaris. Comparative data showed salicylic acid superior to benzoyl peroxide, with adverse effects limited to mild local irritation.

Randomized controlled trial (n=25): Pivotal skin of color salicylic peel evidence for acne PIH melasma oily skin.

Randomized controlled trial: Salicylic vs Jessner equivalent efficacy better tolerability for salicylic.

Randomized controlled trial: Comparable efficacy of salicylic to Jessner.

Clinical study: Salicylic peel for photoaging secondary indication.

Clinical study: Direct head to head AHA vs BHA for acne.

Clinical study: Definitive evidence that salicylic does NOT increase UV sensitivity unlike glycolic; key differentiator from AHA family.

Systematic review of keratolytics and emollients in psoriasis therapy: salicylic acid is a key keratolytic that removes psoriatic scale and improves penetration of co-applied topical agents; supports salicylic acid as an evidence-based adjunctive (descaling) treatment rather than a standalone therapy.

Comprehensive review: salicylic acid (2%) is the only lipophilic BHA, enabling comedolytic and anti-inflammatory activity within the pilosebaceous unit; effective for acne vulgaris, melasma, photodamage, and keratosis pilaris; 20-30% SA peels show efficacy comparable to glycolic acid peels with lower erythema risk in Fitzpatrick IV-VI

Single-blind RCT (n=46, 12 weeks) in mild-to-moderate acne comparing salicylic acid 3% plus clindamycin with tretinoin 0.05% plus clindamycin: both significantly reduced inflammatory and non-inflammatory lesion counts; tretinoin acted faster (significant by week 2) but groups were comparable at 12 weeks, and both were well tolerated.

This review of four placebo-controlled clinical studies and a comedolytic assay found that 0.5% and 2% salicylic acid pads reduced the number and severity of acne lesions in mild-to-moderate acne vulgaris. Comparative data showed salicylic acid superior to benzoyl peroxide, with adverse effects limited to mild local irritation.

Randomized controlled trial (n=25): Pivotal skin of color salicylic peel evidence for acne PIH melasma oily skin.

Randomized controlled trial: Salicylic vs Jessner equivalent efficacy better tolerability for salicylic.

Randomized controlled trial: Comparable efficacy of salicylic to Jessner.

Clinical study: Salicylic peel for photoaging secondary indication.

Clinical study: Direct head to head AHA vs BHA for acne.

Clinical study: Definitive evidence that salicylic does NOT increase UV sensitivity unlike glycolic; key differentiator from AHA family.

Systematic review of keratolytics and emollients in psoriasis therapy: salicylic acid is a key keratolytic that removes psoriatic scale and improves penetration of co-applied topical agents; supports salicylic acid as an evidence-based adjunctive (descaling) treatment rather than a standalone therapy.

Comprehensive review: salicylic acid (2%) is the only lipophilic BHA, enabling comedolytic and anti-inflammatory activity within the pilosebaceous unit; effective for acne vulgaris, melasma, photodamage, and keratosis pilaris; 20-30% SA peels show efficacy comparable to glycolic acid peels with lower erythema risk in Fitzpatrick IV-VI

Single-blind RCT (n=46, 12 weeks) in mild-to-moderate acne comparing salicylic acid 3% plus clindamycin with tretinoin 0.05% plus clindamycin: both significantly reduced inflammatory and non-inflammatory lesion counts; tretinoin acted faster (significant by week 2) but groups were comparable at 12 weeks, and both were well tolerated.

This review of four placebo-controlled clinical studies and a comedolytic assay found that 0.5% and 2% salicylic acid pads reduced the number and severity of acne lesions in mild-to-moderate acne vulgaris. Comparative data showed salicylic acid superior to benzoyl peroxide, with adverse effects limited to mild local irritation.

Randomized controlled trial (n=25): Pivotal skin of color salicylic peel evidence for acne PIH melasma oily skin.

Randomized controlled trial: Salicylic vs Jessner equivalent efficacy better tolerability for salicylic.

Randomized controlled trial: Comparable efficacy of salicylic to Jessner.

Clinical study: Salicylic peel for photoaging secondary indication.

Clinical study: Direct head to head AHA vs BHA for acne.

Clinical study: Definitive evidence that salicylic does NOT increase UV sensitivity unlike glycolic; key differentiator from AHA family.

Systematic review of keratolytics and emollients in psoriasis therapy: salicylic acid is a key keratolytic that removes psoriatic scale and improves penetration of co-applied topical agents; supports salicylic acid as an evidence-based adjunctive (descaling) treatment rather than a standalone therapy.

Comprehensive review: salicylic acid (2%) is the only lipophilic BHA, enabling comedolytic and anti-inflammatory activity within the pilosebaceous unit; effective for acne vulgaris, melasma, photodamage, and keratosis pilaris; 20-30% SA peels show efficacy comparable to glycolic acid peels with lower erythema risk in Fitzpatrick IV-VI

Single-blind RCT (n=46, 12 weeks) in mild-to-moderate acne comparing salicylic acid 3% plus clindamycin with tretinoin 0.05% plus clindamycin: both significantly reduced inflammatory and non-inflammatory lesion counts; tretinoin acted faster (significant by week 2) but groups were comparable at 12 weeks, and both were well tolerated.

This review of four placebo-controlled clinical studies and a comedolytic assay found that 0.5% and 2% salicylic acid pads reduced the number and severity of acne lesions in mild-to-moderate acne vulgaris. Comparative data showed salicylic acid superior to benzoyl peroxide, with adverse effects limited to mild local irritation.

Randomized controlled trial (n=25): Pivotal skin of color salicylic peel evidence for acne PIH melasma oily skin.

Randomized controlled trial: Salicylic vs Jessner equivalent efficacy better tolerability for salicylic.

Randomized controlled trial: Comparable efficacy of salicylic to Jessner.

Clinical study: Salicylic peel for photoaging secondary indication.

Clinical study: Direct head to head AHA vs BHA for acne.

Clinical study: Definitive evidence that salicylic does NOT increase UV sensitivity unlike glycolic; key differentiator from AHA family.

Systematic review of keratolytics and emollients in psoriasis therapy: salicylic acid is a key keratolytic that removes psoriatic scale and improves penetration of co-applied topical agents; supports salicylic acid as an evidence-based adjunctive (descaling) treatment rather than a standalone therapy.

Comprehensive review: salicylic acid (2%) is the only lipophilic BHA, enabling comedolytic and anti-inflammatory activity within the pilosebaceous unit; effective for acne vulgaris, melasma, photodamage, and keratosis pilaris; 20-30% SA peels show efficacy comparable to glycolic acid peels with lower erythema risk in Fitzpatrick IV-VI

Single-blind RCT (n=46, 12 weeks) in mild-to-moderate acne comparing salicylic acid 3% plus clindamycin with tretinoin 0.05% plus clindamycin: both significantly reduced inflammatory and non-inflammatory lesion counts; tretinoin acted faster (significant by week 2) but groups were comparable at 12 weeks, and both were well tolerated.

This review of four placebo-controlled clinical studies and a comedolytic assay found that 0.5% and 2% salicylic acid pads reduced the number and severity of acne lesions in mild-to-moderate acne vulgaris. Comparative data showed salicylic acid superior to benzoyl peroxide, with adverse effects limited to mild local irritation.

Randomized controlled trial (n=25): Pivotal skin of color salicylic peel evidence for acne PIH melasma oily skin.

Randomized controlled trial: Salicylic vs Jessner equivalent efficacy better tolerability for salicylic.

Randomized controlled trial: Comparable efficacy of salicylic to Jessner.

Clinical study: Salicylic peel for photoaging secondary indication.

Clinical study: Direct head to head AHA vs BHA for acne.

Clinical study: Definitive evidence that salicylic does NOT increase UV sensitivity unlike glycolic; key differentiator from AHA family.